Fertility preservation in BRCA mutation carriers.

Area of Science:

• Reproductive medicine and oncology.
• Genetics and cancer risk assessment.

Background:

• Increasing survival rates in young women treated for cancer necessitate fertility preservation discussions.
• BRCA1/BRCA2 mutation carriers face elevated risks of breast and tubo-ovarian cancers, often requiring premature infertility interventions.
• Cancer treatments (chemotherapy, hormonotherapy) and prophylactic surgeries significantly impact fertility in young women and BRCA carriers.

Purpose of the Study:

• To highlight the importance of fertility preservation counseling for young women at risk of ovarian insufficiency.
• To review established and experimental fertility preservation techniques for cancer patients and BRCA carriers.
• To guide the selection of appropriate fertility preservation strategies based on individual patient factors.

Main Methods:

• Review of validated fertility preservation techniques: oocyte and embryo cryopreservation.
• Discussion of experimental methods: ovarian suppression with GnRH-analogues and ovarian tissue cryopreservation.
• Consideration of factors influencing strategy choice: age, chemotherapy type, partner status, cancer type, time, and metastasis risk.

Main Results:

• Fertility preservation options should be offered promptly to all at-risk young women.
• Both validated and experimental techniques can be employed individually or in combination.
• Crucially, fertility preservation interventions must not cause significant delays in initiating cancer treatment.

Conclusions:

• Fertility preservation is a vital component of care for young women undergoing gonadotoxic therapies.
• Personalized counseling and strategy selection are essential for BRCA carriers and other high-risk patients.
• Balancing fertility preservation with timely cancer treatment is paramount.